Actively Recruiting
Zanubrutinib Combined With Rituximab in the Treatment for Patients With Marginal Zone Lymphoma
Led by Henan Cancer Hospital · Updated on 2025-11-18
30
Participants Needed
1
Research Sites
236 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a prospective single arm, multi-center, real-world study to observe the efficacy and safety of ZR (Zanubrutinib combined with Rituximab) in the first-line treatment for patients with marginal zone lymphoma (MZL).
CONDITIONS
Official Title
Zanubrutinib Combined With Rituximab in the Treatment for Patients With Marginal Zone Lymphoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients diagnosed with CD20-positive marginal zone lymphoma by histopathology
- Receiving first-line treatment with Zanubrutinib and Rituximab combination
- No previous systemic treatment before enrollment
- Have at least one measurable lesion: lymph node lesion > 1.5 cm or extranodal lesion > 1.0 cm
- Voluntarily joined the study, signed informed consent, and able to comply with follow-up
You will not qualify if you...
- History of other malignant tumors or active malignant tumors requiring treatment
- Receiving other anti-tumor drugs simultaneously besides Zanubrutinib and Rituximab, except glucocorticoids for symptom control before treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university
Zhengzhou, Henan, China
Actively Recruiting
Research Team
Z
Zhihua Yao, M.D. Ph.D
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here